Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention?

Abstract

Objective:

To investigate the renal-protective effect of lercanidipine in patients undergoing renal artery intervention.

Methods:

A prospective, single-center, cohort study was conducted and patients, 30–75 years of age, with atherosclerotic renal artery stenosis were consecutively enrolled between September 2011 and October 2012. Lercanidipine (10–20 mg/day) was regularly taken after the intervention. Follow up visits were performed at 3 and 6 months after the intervention. Serum creatinine, clinical blood pressure, 24 hour ambulatory blood pressure, pulse wave velocity, and 24 hour urine protein were assessed. Adverse events were recorded.

Results:

In total, 55 patients (mean age 63.5 ± 8.9 years) were enrolled and 52 completed the study. Renal function, estimated glomerular filtration rate (eGFR) and 24 hour urine protein at 3 months after the intervention were not statistically different compared with the baseline. At 6 months after the intervention eGFR significantly increased versus baseline (78 ± 23 ml/min/1.73 m² vs 71 ± 21 ml/min/1.73 m², p = 0.021); 24 hour urine protein decreased significantly (0.02 g [IQR, 0.01–0.1] vs 0.03 g [IQR, 0.01–0.28], p = 0.042). Blood pressure control improved at 3 months and 6 months after the intervention. The need for antihypertensive drugs decreased; clinical systolic blood pressure, diastolic blood pressure and 24 hour average systolic blood pressure and diastolic blood pressure decreased. The pulse wave velocity decreased after 3 and 6 months. At the end of follow-up, none of the following adverse events occurred: death, dialysis, myocardial infarction or stroke. Mild lower extremity edema occurred in only one patient. No other side effects occurred.

Conclusions:

This study showed that lercanidipine can improve renal function in patients undergoing renal artery intervention.

Keywords: :

• 24-hour urine protein
• Lercanidipine
• Renal artery stenting
• Renal function

Transparency

Declaration of funding

Editorial support for this manuscript was funded by Recordati.

Declaration of financial/other relationships

M.P., X.-j.J., H.D., Y.-b.Z., H.-m.Z., H.y.W., and Y.Y. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

CMRO peer reviewers on this manuscript have received an honorarium from CMRO for their review work, but have no relevant financial or other relationships to disclose.

Acknowledgments

Editorial assistance was provided by Chiara Mossali PhD and Luca Giacomelli PhD of Content Ed Net.